Campbell & Co Investment Adviser’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.1M | Buy |
+74,549
| New | +$4.1M | 0.26% | 68 |
|
|
2024
Q3 | – | Sell |
-13,186
| Closed | -$1.09M | – | 1099 |
|
|
2024
Q2 | $1.09M | Sell |
13,186
-18,924
| -59% | -$1.56M | 0.09% | 332 |
|
|
2024
Q1 | $2.8M | Buy |
32,110
+28,556
| +803% | +$2.49M | 0.24% | 73 |
|
|
2023
Q4 | $343K | Buy |
+3,554
| New | +$343K | 0.03% | 869 |
|
|
2023
Q3 | – | Sell |
-3,365
| Closed | -$292K | – | 954 |
|
|
2023
Q2 | $292K | Buy |
+3,365
| New | +$292K | 0.05% | 678 |
|
|
2023
Q1 | – | Sell |
-12,405
| Closed | -$1.28M | – | 815 |
|
|
2022
Q4 | $1.28M | Buy |
12,405
+7,955
| +179% | +$823K | 0.31% | 50 |
|
|
2022
Q3 | $377K | Sell |
4,450
-7,275
| -62% | -$616K | 0.09% | 404 |
|
|
2022
Q2 | $972K | Buy |
+11,725
| New | +$972K | 0.26% | 87 |
|
|
2022
Q1 | – | Sell |
-5,950
| Closed | -$526K | – | 702 |
|
|
2021
Q4 | $526K | Buy |
+5,950
| New | +$526K | 0.18% | 183 |
|
|
2019
Q2 | – | Sell |
-10,671
| Closed | -$948K | – | 537 |
|
|
2019
Q1 | $948K | Buy |
+10,671
| New | +$948K | 0.47% | 28 |
|
|
2017
Q3 | – | Sell |
-3,734
| Closed | -$339K | – | 357 |
|
|
2017
Q2 | $339K | Buy |
+3,734
| New | +$339K | 0.32% | 104 |
|
|
2017
Q1 | – | Sell |
-2,902
| Closed | -$240K | – | 154 |
|
|
2016
Q4 | $240K | Buy |
+2,902
| New | +$240K | 0.74% | 60 |
|
|
2015
Q4 | – | Sell |
-4,589
| Closed | -$483K | – | 93 |
|
|
2015
Q3 | $483K | Buy |
+4,589
| New | +$483K | 0.32% | 109 |
|
|
2014
Q2 | – | Sell |
-43,550
| Closed | -$2.97M | – | 163 |
|
|
2014
Q1 | $2.97M | Buy |
43,550
+33,953
| +354% | +$2.32M | 1.2% | 27 |
|
|
2013
Q4 | $675K | Sell |
9,597
-21,203
| -69% | -$1.49M | 0.15% | 148 |
|
|
2013
Q3 | $2.22M | Sell |
30,800
-67,236
| -69% | -$4.85M | 0.44% | 79 |
|
|
2013
Q2 | $5.47M | Buy |
+98,036
| New | +$5.47M | 1.06% | 23 |
|